Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

HealthDay News — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Researchers have established that the application of once-weekly semaglutide in patients with type 2 diabetes (T2D) increases ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...